Gabelli Enterprise Mergers & Acquisitions Fund on Organon & Co.
Thesis
Sun Pharmaceuticals agreed to acquire Organon for $14.00 per share in cash. The deal remained subject to shareholder and antitrust approvals at the time of the commentary. Gabelli expects completion in early 2027, leaving the merger spread as the core event-driven return opportunity.
“It is expected to be completed in early 2027.”
Key risks
- The announced acquisition may not be completed
- Antitrust approvals may delay or prevent closing